A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors
Interventions: DRUG: Venetoclax|DRUG: Rovalpituzumab Tesirine|DRUG: ABBV-181
Sponsor: AbbVie